Used in immunotherapy for cancer treatment, this antibody targets GITR (glucocorticoid-induced TNFR-related protein) on regulatory T cells and effector T cells to modulate immune responses. It enhances T cell activation and suppresses the immunosuppressive activity of regulatory T cells within the tumor microenvironment, promoting anti-tumor immunity. Investigated in clinical trials for solid tumors, it is often combined with other checkpoint inhibitors like anti-PD-1 antibodies to improve therapeutic efficacy. Its application focuses on boosting the body’s immune response against cancer cells, particularly in resistant or advanced malignancies.